PoP: Redemption video has hid in plain sight since 2012, elicits former devs' response.

Blake Lively will star in "Dark Days at the Magna Carta," a post-apocalyptic thriller that's being developed at Netflix as a possible trilogy. Michael Paisley will write the screenplay for "Dark Days at the Magna Carta," set amid a catastrophic event and centering on a woman going to extreme lengths to survive and save her […]

Robert De Niro has heaped praise on Andrew Cuomo's response to the coronavirus pandemic, while also taking the chance to attack Trump, too.

In anticipation for a technical event that may be a new catalyst, Bitcoin has rallied to more than US$9,000 from around US$6,000 just a month ago

We love these products, and we hope you do too. E! has affiliate relationships, so we may get a small share of the revenue from your purchases. Items are sold by the retailer, not...

Celebrities from across the globe came together Saturday night to lift their fans’ spirits as the world continues to cope with the coronavirus pandemic.

Canadian actors, musicians and public figures came together on Saturday night for a televised special to support frontline and essential workers, and to raise funds for Food Banks Canada.

There are many challenges to developing a vaccine that will be successful against COVID-19.eamesBot / Shutterstock

Wayne Koff is one of the world’s experts on vaccine development, the president and CEO of the Human Vaccines Project. He possesses a deep understanding of the opportunities and challenges along the road to a safe and effective vaccine against COVID-19. He has won prestigious awards, published dozens of scientific papers, held major positions in academia, government, industry, and nonprofit organizations. But Koff, 67, has never produced a successful vaccine.

“I have been an abject failure,” he says. He smiles with a charming, self-deprecating sense of humor. “That’s what the message is.”

The real reason for Koff’s lack of success is that he spent most of his career searching for a vaccine against HIV, the virus that causes AIDS. It remains, as he and many others put it, “the perfect storm” of a viral infection resistant to a vaccine development. Almost 40 years after doctors first recognized the disease in five men in Los Angeles—and 70 million people have been infected worldwide—there are no adequate animal models. Neutralizing antibodies, the backbone of many vaccines, do not stop it, and most importantly, HIV begins its assault on the body by attacking CD4 T cells, which serve as the command center of much of the immune system.

As for COVID-19, “We’re all hoping this one is going to be easier,” says Koff, a slight, bearded man with thick, curly salt-and-pepper hair. “There are research issues that still have to be addressed on a COVID vaccine. But they are a lot more straightforward than what we were dealing with in HIV.”

Let’s say we have a vaccine in 18 months. How do you make 1 billion doses or 4 billion doses or whatever it’s going to take to immunize everybody?

Koff and others started the Human Vaccines Project in 2016, modeled on the Human Genome Project. The project works with industry and academia to study the human immune system and develop vaccines, incorporating every modern-day tool, including artificial intelligence, computational biology, and big data sets. Today it is partnered with the Harvard T.H. Chan School of Public Health.

With COVID-19, Koff says, scientists “know the target is the spike protein binding site.” This is where the proteins sticking out from the virus attach to the cells in the human respiratory system. “If you can elicit antibodies against those proteins, they should be neutralizing.” He puts a strong emphasis on should. To prove antibodies will prevent infection, scientists must watch a population of people who’ve been infected for months or longer. It’s a good bet, based on similar viruses, that antibodies will appear and protect—although no one right now can predict how long and how well.

Depending on which count you use, more than 70 companies, universities, and other institutions are offering candidate vaccines. Koff says the real number of companies is lower. During the AIDS crisis, he says, “a lot of people claimed they had an experimental HIV vaccine in development. Some of those were a one-person lab who had created a paper company to attract investors.”

But even with a lower number, almost everyone involved in the search for a vaccine agrees that several different approaches from different research organizations need to proceed in parallel. The world does not have the time to bet on one horse. The race will be neither simple nor cheap.

“The probability of success, depending on whose metric is used in vaccines, is somewhere between 6 and 10 percent of candidate vaccines that make it from the animal model through licensure,” Koff says. “That process costs $1 billion or more. So you can do the math.”

Koff sees big potential problems at the outset. “In the best of all worlds, let’s say we have a vaccine in 18 months. Who knows where the epidemic is going to be then and what its impact is going to be? How do you make 1 billion doses or 4 billion doses or whatever it’s going to take to immunize everybody? Will we need one dose or two or three? These are issues people just haven’t faced before.”

COVID-19 also presents some unique dangers for vaccine safety. Based on how the virus behaves when it infects some people, there’s a chance a vaccine could dangerously overstimulate the immune system, a reaction called immune enhancement. “I’m hoping it’s more theoretical than real,” Koff says. “But that has to be addressed and it may slow down the entire process.” To ensure safety, he says, “It may mean we have to test the vaccine in a larger number of people. It’s one thing to do a 50-person trial in healthy adults as a safety signal. It’s another thing to run a trial of 4,000 or 5000 or more individuals.”

The world does not have the time to bet on one horse. The race will be neither simple nor cheap.

A virus also sometimes causes mysterious, potentially deadly blood clots. This means an experimental vaccine could hypothetically induce the same damage. “This is a bad bug,” Koff says. “We’re just starting to understand that pathogenesis.”

A big question is who should be the first volunteers for widespread vaccine testing. “Who are the high-risk groups?” asks Koff. “Is it nursing-home residents and staff, health-care workers and people on the front lines, or people someplace else like grocery stores? We must also make sure a vaccine is effective for the elderly and people in the developing world.”

Many vaccines work well in young and healthy people but not in older adults because immunity declines with age. Influenza vaccine is a prime example. Rotavirus vaccine, which protects against the deadliest killer—diarrheal disease in children—works better in the developed world. In the developing world, the virus often circulates year-round. Infants get antibodies from breast milk but not enough to prevent disease. Worse, those antibodies can make the vaccine less effective.

Another hypothetical obstacle is that a mutation in the COVID-19 virus could render a vaccine designed today less effective in the future. While the virus mutates frequently, so far there has been little change in the critical part of the spike that binds to human cells.

Of course, neither Koff nor all the others working for a COVID-19 vaccine focus solely on the potential obstacles. At one time, all vaccines against viruses either killed viruses, such as the Salk polio vaccine, or rendered them harmless, such as the Sabin polio vaccine. Now there is a multiplicity of ways to stimulate an immune response to prevent infection or reduce the consequences. These include genetically engineered protein subunits (peptides) or virus-like particles. Such approaches have led to successful vaccines against hepatitis B and human papilloma virus, which causes cervical cancer. Researchers now use “vectors”—harmless viruses attached to the protein subunits and virus particles to transmit them into the body. There are also many new adjuvants, chemicals that boost immune response to a vaccine.

Newer platforms include direct injection of messenger-RNA. M-RNA is the chemical used to translate the information in DNA into proteins in all cells. The Moderna Company, which received a $483 million grant from the U.S. government, and has begun early clinical trials, uses m-RNA to try to make the body produce proteins to protect against the COVID-19 virus. INOVIO Pharmaceuticals uses pieces of DNA called plasmids to achieve the same objective. It has also begun phase 1 studies.

“There are about eight platforms, and it would be good to see a couple vaccines in each of those advance,” Koff says. Predicting which of these most likely to succeed or fail he says would be “simply foolish.”

Many groups, including the Human Vaccines Initiative, are plotting routes to test any possible vaccine more quickly than tradition dictates with an “adaptive trial design.” Usually trials begin with a phase 1 study of some 50 healthy people to search for any immediate signs of toxicity, then moves onto about 200 people in a phase 2, still looking for hazards and a signal of immunity, and then to phase 3 in thousands of people. But the plan here is to start phases 2 and 3 even before its predecessors are finished, and keep recruiting additional volunteers so long as no danger signals arise.

Good animal models are appearing almost daily. Macaque monkeys, hamsters, and genetically engineered mice have all been infected in the laboratory and could determine whether potential vaccines exhibit various types of immunity. Members of Congress from both sides of the aisle have suggested that healthy human volunteers should be allowed to agree to be test subjects, allowing themselves to be infected. Stanley Plotkin, a vaccine researcher at the University of Pennsylvania, was among the first to suggest the idea.

Arthur Caplan, a bioethicist at New York University, says that “deliberately causing disease in humans is normally abhorrent.” But COVID-19 is anything but a normal circumstance. In this case, Caplan says, “asking volunteers to take risks without pressure or coercion is not exploitation but benefitting from altruism.” At least 1,500 people have already volunteered to be such human guinea pigs, although none of the experimental vaccines is far enough along to try such challenging experiments.

Koff says the key to a successful vaccine is a cooperative effort. “It’s going to take a whole different way of thinking to move this onto the expedited train,” he says. “The old dog-eat-dog, ‘I’m going to beat you to the end of the game,’ isn’t going to help us with this.” Seth Berkley, who worked with Koff at the International AIDS Vaccine Initiative, and now heads GAVI, an international vaccine organization, agrees that a COVID-19 vaccine needs a Manhattan Project approach. “An initiative of this scale won’t be easy,” Berkley says. “Extraordinary sharing of information and resources will be critical, including data on the virus, the various vaccine candidates, vaccine adjuvants, cell lines, and manufacturing advances.”

Koff has no regrets about spending so many years on an AIDS vaccine without results. He learned a great deal, he says, which he’s putting to work in the COVID-19 crisis. “The reason COVID-19 vaccines should be a lot easier is because most of the platforms, the novel approaches, and the clinical infrastructure for the testing of vaccines, came out of HIV.” He pauses. “We’re far better prepared.”

Robert Bazell is an adjunct professor of molecular, cellular, and developmental biology at Yale. For 38 years, he was chief science correspondent for NBC News.

Florida health officials have halted the publication of up-to-the-minute death statistics related to the coronavirus pandemic that have, by law, been compiled by medical examiners in the state.

Sara Cherry, a microbiologist at the University of Pennsylvania, feels safer at work than almost anywhere else. That’s because she works inside a biosafety level 3 laboratory on the Penn campus in Philadelphia, where she is the scientific director of the High-Throughput Screening Core.

Thousands of people have volunteered to be exposed to coronavirus if it means a vaccine can be developed more quickly. Should we let them?

Figuring out how to stage the nation’s largest and most important political gatherings will be tricky in the COVID-19 era. And while officials in both parties say they’re still planning for in-person conventions, pulling that off will be a lot easier said than done. 

With major sports leagues preparing for the eventuality of restarting behind closed doors amid the coronavirus pandemic, NBA commissioner Adam Silver reportedly took the concept to the next level on Friday.

To mark our 175th anniversary year, we feature a different front page each week from past editions of the Ottawa Citizen.

Chris Labelle has a hard time getting through his latest song, Frontliners, without becoming emotional.  The Ottawa country singer wrote the tune — an unabashedly sentimental anthem of gratitude for front-line workers — during one of the sleepless nights leading up to the birth of his first child with wife Julie. Their baby boy, Grayson, […]

From the #MetGalaChallenge to high fashion Twitter's Met Gala

Star also selling Instagram follow-backs for $250

Many fans praised Helen McRory's 'bad-ass' performance and the unexpected musical sequence

Original 'Who Wants to Be a Millionaire?' host in feud with 'coughing major'

The former assistant to the jailed producer talks to Olivia Petter about her attempted rape allegation against Harvey Weinstein, why his lawyers must be held to account, and the damaging myths we attach to rape survivors and perpetrators

Thirty years on from Kelsey Grammer's remarkable cartoon debut, Louis Chilton looks at the legacy of one of the most endearing felons in fiction

The Advertising Standards Authority received 155 complaints

(Clover Music)
With this long-awaited fourth album, the former teen idol has finally arrived as the kind of artist she was always meant to be

‘Look at me now” is a fitting opening line for Good to Know, the fourth studio album from R&B singer JoJo. The artist has been on a storied journey through the music industry and the public eye: first emerging as the 13-year-old singer of Leave (Get Out), she then spent years mired in legal disputes with her label that prevented her releasing music. After reigniting her passionate fanbase with a string of independent, darker-sounding mixtapes (and one viral Drake cover), she released Mad Love, her long-delayed third album, in 2016. But Good to Know, released on her own imprint Clover Music, with its themes of independence and self-knowledge, carries with it a sense that she has finally arrived as the kind of artist she was always meant to be.

The musician on DIY smooching, dinner parties and why he won’t do interviews between 1.45pm and 2.15pm

Raised in Sheffield, Heaton, 57, founded the Housemartins in the early eighties. They had hit singles with Happy Hour and Caravan Of Love before splitting in 1988. Heaton then formed the Beautiful South, releasing 10 albums before disbanding in 2007. With former band member Jacqui Abbott, Heaton has released three albums, the most recent being Manchester Calling. He is married with three children and lives in Manchester.

What is the trait you most deplore in yourself?
Forgetfulness.

Herd immunity means that after a certain percentage of a population is immune to a disease, the whole population is. This is usually achieved through vaccination but some are not convinced.

News Corp is campaigning full-bore for the US president, with reports of a Wuhan lab ‘intelligence’ dossier being seeded across its empire

In liberal democracies, the integrity, impartiality and professionalism of intelligence agencies matters. That’s why it is essential that intelligence agencies remain aloof, not only from the political debates of the day, but also from the policy decisions that individual governments may take. The intelligence community’s core task is to provide brutally realistic analysis on the threat environments we face so that governments can then make the best-informed policy decisions possible to preserve our common security.

The failures of the intelligence community before the Iraq war, the gullibility of much of the western media, as well as the cynical manipulation of both by the political class of the day, provide us with a stark reminder of what can go radically wrong. On 8 September 2002 the New York Times published one of this century’s most consequential news articles. The front-page story, supplied by the Bush administration, claimed that Saddam Hussein had stepped up his quest for weapons of mass destruction by acquiring key components for a nuclear weapon. In the UK, the Blair government’s “dodgy dossier” compounded the error. John Howard did the same in Australia. The problem was that it just wasn’t true. These were over-egged stories designed to soften the public up for what would become a disastrous war.

The TV star is adding some sparkle to her household tasks

Price said her 'phobia of water' made things difficult during the tough course

The fundraising veteran has released a charity single with Michael Ball

Andersson said it has been "humbling" to return to her old profession during the coronavirus crisis

The episode also saw the star close her shop as the pandemic took hold

The course of true love never did run smooth, after all

The actor was best known for his Bollywood fame and roles in films like Slumdog Millionaire and Life of Pi

A round of applause for our carers

For the next instalment of our new series of letters capturing tales and reflections during lockdown, Zoe Paskett finds the family traditions she once resisted have become the highlight of her week

Colour me happy — a bright way to chill out

In the latest instalment in our series of thoughts and reflections during lockdown, Suzannah Ramsdale reassesses what's actually important

Lockdown is about to get considerably more fash-un

Networking and expanding job opportunities during lockdown is easier than you think. Laura Hampson speaks to career coach and consultant, Hannah Salton to see how it's done

Chess-based, card-based, roguelike dungeon crawler. And you might as well throw puzzler on top of it too. That’s quite a …

Continue reading "‘Pawnbarian’ is a Chess-Based, Card-Based, Roguelike Dungeon Crawler Coming to Mobile and Desktop"

Every year on March 8th, people around the world celebrate International Women’s Day, and at Music Canada we’re showing our commitment to gender equality by celebrating this year’s theme of #EachForEqual. The theme draws from a notion of ‘Collective Individualism,’ and the way that our individual actions can collectively make change and help create a […]

The post Music Canada Celebrates International Women’s Day 2020 appeared first on Music Canada.

The 23-year-old actress has revealed via Instagram that she'll be voicing the part of an eight-year-old girl in an upcoming episode

Blake Lively is producing with Shawn Levy, her husband Ryan Reynolds's frequent collaborator.

On Monday, Australia's Prime Minister Malcolm Turnbull announced he had removed the titles of "knights" and "dames" from the Order of Australia, a formal award system that honours those who provide a great service to Australia.

The two archaic titles were only brought back last year in a controversial move by former prime minister Tony Abbott. In a decision that made many question Abbott's leadership, the first knighthood was awarded to Prince Philip, the Duke of Edinburgh — a man who has only been to Australia a handful of times.